| CB1 cannabinoid receptors and on-demand defense against excitotoxicity G Marsicano, S Goodenough, K Monory, H Hermann, M Eder, A Cannich, ... Science 302 (5642), 84-88, 2003 | 1417 | 2003 |
| Mitochondrial CB1 receptors regulate neuronal energy metabolism G Bénard, F Massa, N Puente, J Lourenço, L Bellocchio, E Soria-Gómez, ... Nature neuroscience 15 (4), 558-564, 2012 | 624 | 2012 |
| The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system AC Campos, Z Ortega, J Palazuelos, MV Fogaça, DC Aguiar, ... International Journal of Neuropsychopharmacology 16 (6), 1407-1419, 2013 | 323 | 2013 |
| Endocannabinoids drive the acquisition of an alternative phenotype in microglia M Mecha, A Feliú, FJ Carrillo-Salinas, A Rueda-Zubiaurre, ... Brain, behavior, and immunity 49, 233-245, 2015 | 219 | 2015 |
| A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease JL López-Sendón Moreno, J García Caldentey, P Trigo Cubillo, ... Journal of neurology 263, 1390-1400, 2016 | 146 | 2016 |
| Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis S Ortega‐Gutiérrez, E Molina‐Holgado, Á Arévalo‐Martín, F Correa, ... The FASEB journal 19 (10), 1338-1340, 2005 | 136 | 2005 |
| Novel inhibitors of fatty acid synthase with anticancer activity T Puig, C Turrado, B Benhamú, H Aguilar, J Relat, S Ortega-Gutiérrez, ... Clinical Cancer Research 15 (24), 7608-7615, 2009 | 130 | 2009 |
| A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines T Puig, H Aguilar, S Cufí, G Oliveras, C Turrado, S Ortega-Gutiérrez, ... Breast Cancer Research 13, 1-13, 2011 | 124 | 2011 |
| Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer E Pérez-Gómez, C Andradas, S Blasco-Benito, MM Caffarel, ... Journal of the National Cancer Institute 107 (6), djv077, 2015 | 122 | 2015 |
| A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis G Hernández‐Torres, M Cipriano, E Hedén, E Björklund, Á Canales, ... Angewandte Chemie 126 (50), 13985-13990, 2014 | 114 | 2014 |
| Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures S Ortega‐Gutiérrez, E Molina‐Holgado, C Guaza Glia 52 (2), 163-168, 2005 | 112 | 2005 |
| The constitutive production of the endocannabinoid 2‐arachidonoylglycerol participates in oligodendrocyte differentiation O Gomez, A Arevalo‐Martin, D Garcia‐Ovejero, S Ortega‐Gutierrez, ... Glia 58 (16), 1913-1927, 2010 | 111 | 2010 |
| Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase ML López-Rodríguez, A Viso, S Ortega-Gutiérrez, CJ Fowler, G Tiger, ... Journal of medicinal chemistry 46 (8), 1512-1522, 2003 | 109 | 2003 |
| Monoacylglycerol lipase (MAGL) as a promising therapeutic target A Gil-Ordóñez, M Martín-Fontecha, S Ortega-Gutiérrez, ... Biochemical pharmacology 157, 18-32, 2018 | 107 | 2018 |
| Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake S Ortega-Gutiérrez, EG Hawkins, A Viso, ML López-Rodríguez, BF Cravatt Biochemistry 43 (25), 8184-8190, 2004 | 107 | 2004 |
| Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels E De Lago, S Petrosino, M Valenti, E Morera, S Ortega-Gutierrez, ... Biochemical pharmacology 70 (3), 446-452, 2005 | 93 | 2005 |
| Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors ML López-Rodríguez, A Viso, S Ortega-Gutiérrez, I Lastres-Becker, ... Journal of medicinal chemistry 44 (26), 4505-4508, 2001 | 91 | 2001 |
| UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the … E De Lago, J Fernández-Ruiz, S Ortega-Gutiérrez, A Cabranes, G Pryce, ... European neuropsychopharmacology 16 (1), 7-18, 2006 | 86 | 2006 |
| UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide E de Lago, J Fernández-Ruiz, S Ortega-Gutiérrez, A Viso, ... European journal of pharmacology 449 (1-2), 99-103, 2002 | 81 | 2002 |
| New synthetic inhibitors of fatty acid synthase with anticancer activity C Turrado, T Puig, J García-Cárceles, M Artola, B Benhamú, ... Journal of medicinal chemistry 55 (11), 5013-5023, 2012 | 79 | 2012 |
